Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

4:09 PM ET Form 4
Insider Selling Nasdaq, Inc. NDAQ

Nasdaq EVP, CIO Bradley J. Peterson Sells $545K of Stock

Bradley J. Peterson, EVP, CIO, sold 5,000 shares of Nasdaq, Inc. at $109.07 a share, worth $545K in total on Nov 12, 2026. Shares held after the trade: 104,306 (-4.6%).

Value
$545K
Shares
5,000
Price
$109.07
Role
EVP, CIO
Holding change
-4.6%
Trade date
Nov 12, 2026
4:09 PM ET Form 4
Insider Selling Lifevantage Corp LFVN

Lifevantage Director Michael A. Beindorff Sells $48.9K of Stock

Michael A. Beindorff, Director, sold 10,000 shares of Lifevantage Corp at $4.89 a share, worth $48.9K in total on Nov 12, 2026. Shares held after the trade: 31,625 (-24.0%).

Value
$48.9K
Shares
10,000
Price
$4.89
Role
Director
Holding change
-24.0%
Trade date
Nov 12, 2026
4:09 PM ET Form 4
Insider Selling Dyne Therapeutics, Inc. DYN

Dyne Therapeutics CFO Erick Lucera Sells $33.5K of Stock

Erick Lucera, CFO, sold 1,991 shares of Dyne Therapeutics, Inc. at $16.82 a share, worth $33.5K in total on Nov 13, 2026. Shares held after the trade: 117,775 (-1.7%).

Value
$33.5K
Shares
1,991
Price
$16.82
Role
CFO
Holding change
-1.7%
Trade date
Nov 13, 2026
4:09 PM ET Form 4
Insider Selling Aflac Inc AFL

Aflac Insider Japan Post Holdings Co. Ltd. Sells $1.64M of Stock

Japan Post Holdings Co. Ltd. sold 12,900 shares of Aflac Inc at $126.76 to $129.08 a share (average $126.99) in 3 transactions, worth $1.64M in total on Nov 12, 2026. Shares held after the trade: 50,095,429 (-0.0%).

Value
$1.64M
Shares
12,900
Average price
$126.99
Holding change
-0.0%
Trade date
Nov 12, 2026
4:09 PM ET Form 4
Insider Selling Fennec Pharmaceuticals Inc. FENC

Fennec Pharmaceuticals Director Marco Maria Brughera Sells $240K of Stock

Marco Maria Brughera, Director, sold 20,000 shares of Fennec Pharmaceuticals Inc. at $12.00 a share, worth $240K in total on Nov 13, 2026. Shares held after the trade: 0 (-100.0%).

Value
$240K
Shares
20,000
Price
$12.00
Role
Director
Holding change
-100.0%
Trade date
Nov 13, 2026
4:09 PM ET Form 4
Insider Selling TheRealReal, Inc. REAL

TheRealReal CAO Steve Ming Lo Sells $1.04M of Stock

Steve Ming Lo, CAO, sold 73,298 shares of TheRealReal, Inc. at $14.20 to $14.27 a share (average $14.23) in 2 transactions, worth $1.04M in total between Nov 12, 2026 and Nov 13, 2026. Shares held after the trade: 83,542 (-30.2%).

Value
$1.04M
Shares
73,298
Average price
$14.23
Role
CAO
Holding change
-30.2%
Trade date
Nov 12, 2026 to Nov 13, 2026
4:09 PM ET Form 4
Insider Selling Concentra Group Holdings Parent, Inc. CON

Concentra Group Holdings Parent Insider Greg M. Gilbert Sells $781K of Stock

Greg M. Gilbert sold 18,194 shares of Concentra Group Holdings Parent, Inc. at $42.90 a share, worth $781K in total on Nov 12, 2026. Shares held after the trade: 130,640 (-12.2%).

Value
$781K
Shares
18,194
Price
$42.90
Holding change
-12.2%
Trade date
Nov 12, 2026
4:08 PM ET 10-Q
Financial Results Soluna Holdings, Inc SLNH ▶ Call

Soluna Holdings Q3 2026 Results: Net Loss of $28.7M, Loss Widens

Soluna Holdings, Inc. is a non-accelerated filer and smaller reporting company focused on Bitcoin mining and high-performance computing (HPC) data centers. As of November 12, 2026, the company reported 258,827,640 shares of common stock outstanding and is expanding its services into GPU-as-a-Service and AI-related infrastructure.

Key figure
Net loss $28.7M
4:08 PM ET 10-Q
Financial Results VirnetX Holding Corp VHC

VirnetX Holding Q3 2026 Results: Net Loss of $4.51M, Loss Widens

VirnetX Holding Corp reported zero revenue for the nine months ended September 30, 2026, and a net loss of $13.4 million. The company issued a going concern warning, stating that its current cash and cash equivalents of $10.1 million are insufficient to fund operations for the next twelve months.

Key figure
Net loss $4.51M
4:08 PM ET 10-Q
Financial Results Global Gas Corp HGAS

Global Gas Q3 2026 Results: Net Loss of $19.7K, Loss Narrows

Global Gas Corporation reported a net loss of $87,641 for the nine months ended September 30, 2026, compared to a loss of $21,844 in the prior year period. The company remains a nascent project developer with zero revenue in 2026 and a total stockholders' deficit of $383,971 as of the reporting date.

Key figure
Net loss $19.7K
4:08 PM ET 10-Q
Financial Results 5E Advanced Materials, Inc. FEAM

5E Advanced Materials Q1 2026 Results: Net Loss of $13.1M, Loss Widens

5E Advanced Materials, Inc. has transitioned from a pre-revenue development stage company to a revenue-generating producer following a recent acquisition. However, the company reports substantial doubt regarding its ability to continue as a going concern, citing the need for significant additional funding to maintain operations and advance the Fort Cady Project.

Key figure
Net loss $13.1M
4:08 PM ET 10-Q
Financial Results Entrepreneur Universe Bright Group EUBG

Entrepreneur Universe Bright Group Q3 2026 Results: Net Loss of $222K

Entrepreneur Universe Bright Group reported a net loss of $178,346 for the nine months ended September 30, 2026, compared to a net income of $1,001,450 in the prior year period, driven by a 35% decline in revenue. During the period, the company expanded into the Fintech sector through the acquisition of HengYing International Investment Limited and initiated commercial lending activities.

Key figure
Net loss $222K
4:08 PM ET 10-Q
Financial Results Dare Bioscience, Inc. DARE

Dare Bioscience Q3 2026 Results: Net Loss of $3.16M, Loss Narrows

For the nine months ended September 30, 2026, Dare Bioscience reported a net loss of $9.14 million, an improvement from the $11.96 million loss in the prior year period. The company expanded its business model to include a dual-path approach for market access via 503B outsourcing facilities while continuing traditional FDA approval pathways.

Key figure
Net loss $3.16M
4:08 PM ET 10-Q
Financial Results Pathfinder Bancorp, Inc. PBHC

Pathfinder Bancorp Q3 2026 Results: Net Income $2.07M, Up 230.5% YoY

For the nine months ended September 30, 2026, Pathfinder Bancorp reported net income of $7.15 million, a significant increase from $3.63 million in the prior year period, primarily driven by a $5.1 million reduction in the provision for credit losses. Total assets grew to $1.49 billion, while shareholders' equity decreased slightly to $118.8 million due to an increase in accumulated other comprehensive loss from available-for-sale securities.

Key figure
Net income $2.07M · +230.5% YoY
4:08 PM ET 10-Q
Financial Results Cycurion, Inc. CYCU

Cycurion Q3 2026 Results: Net Loss of $2.92M, Loss Narrows

Cycurion, Inc. reported revenue of $12.4 million for the nine months ended September 30, 2026, compared to $11.6 million in the prior year period. The company significantly reduced its operating loss to $7.2 million from $18.4 million year-over-year, primarily due to the absence of one-time business combination expenses incurred in 2025.

Key figure
Net loss $2.92M
4:08 PM ET 10-Q
Financial Results Security Midwest Bancorp, Inc. SBMW

Security Midwest Bancorp Q3 2026 Results: Net Income $445K, Up 58.2% YoY

Security Midwest Bancorp reported net income of $1.25 million for the nine months ended September 30, 2026, an increase from $1.03 million in the prior year period. The company experienced significant loan growth, with net loans increasing to $137.0 million from $117.8 million at year-end 2025, while total assets remained stable at approximately $255.9 million.

Key figure
Net income $445K · +58.2% YoY
4:08 PM ET 10-Q
Financial Results Acrivon Therapeutics, Inc. ACRV

Acrivon Therapeutics Q3 2026 Results: Net Loss of $17.9M, Loss Narrows

For the nine months ended September 30, 2026, Acrivon Therapeutics reported a net loss of $54.9 million, a slight improvement from the $58.9 million loss in the prior year period. The company's cash position decreased to $47.5 million from $41.5 million at year-end 2025, while short-term investments dropped significantly from $77.1 million to $30.2 million.

Key figure
Net loss $17.9M
4:08 PM ET 10-Q
Financial Results Zoned Properties, Inc. ZDPY

Zoned Properties Q3 2026 Results: Net Income $5.31M, Up 3320.0% YoY

Zoned Properties reported a significant increase in net income to $5.33 million for the nine months ended September 30, 2026, primarily driven by a $5.91 million gain from the sale of rental properties classified as discontinued operations. The company's cash position strengthened substantially to $10.46 million, while continuing operations remained pre-revenue with an operating loss of $1.12 million.

Key figure
Net income $5.31M · +3320.0% YoY
4:08 PM ET 10-Q
Financial Results Myseum.AI, Inc. MYSE

Myseum.AI Q3 2026 Results: Net Loss of $1.95M, Loss Widens

Myseum.AI, Inc. reported a significant net loss of $7.87 million for the nine months ended September 30, 2026, compared to a $4.21 million loss in the prior year, driven by increased operating expenses and a $2.58 million unrealized loss on non-traded equity securities. Total assets decreased from $7.20 million to $3.59 million during the period, primarily due to the devaluation of investments and cash burn from operations.

Key figure
Net loss $1.95M
3:48 PM ET 10-Q
Financial Results Sundance Strategies, Inc. SUND

Sundance Strategies Q2 2026 Results: Net Loss of $191K, Loss Widens

Sundance Strategies, Inc. reported a net loss of $404,106 for the six months ended September 30, 2026, compared to a loss of $798,614 in the prior year period. The company generated no revenue during these periods and continues to operate with a significant stockholders' deficit of $7.5 million as it transitions its business model toward professional services for the life settlement market.

Key figure
Net loss $191K
3:45 PM ET 10-Q
Financial Results KiNRG, Inc. BYOP

KiNRG Q3 2026 Results: Turns Profitable, Net Income $10.9M

KiNRG, Inc. reported a significant turnaround for the nine months ended September 30, 2026, with net income of $26.8 million compared to a net loss of $1.1 million in the prior year period. This growth was driven by a massive increase in revenue to $867.3 million, primarily following a major acquisition that expanded the company's contract assets and receivables.

Key figure
Net income $10.9M
3:44 PM ET Form 4
Insider Selling Gilead Sciences, Inc. GILD

Gilead Sciences Insider Kelly A. Kramer Sells $1.76M of Stock

Kelly A. Kramer sold 10,376 shares of Gilead Sciences, Inc. at $168.23 to $171.44 a share (average $169.76) in 4 transactions, worth $1.76M in total on Nov 12, 2026. Shares held after the trade: 1,339 (-13.0%).

Value
$1.76M
Shares
10,376
Average price
$169.76
Holding change
-13.0%
Trade date
Nov 12, 2026
3:44 PM ET 8-K
Financial Results Retractable Technologies Inc RVP

Retractable Technologies Financial Results

Retractable Technologies reported Q3 2026 total net sales of $14.1 million, a significant increase from $10.1 million in the prior year period, driven by a 64% increase in unit sales of EasyPoint products. Despite the revenue growth, the company recorded an operating loss of $4.1 million for the quarter as it continues to manage domestic production shifts and tariff mitigation efforts.

Term
Q3 2026
3:44 PM ET 8-K
Leadership Change Perfect Moment Ltd. PMNT

Perfect Moment Leadership Change

Perfect Moment announced a major leadership overhaul, appointing Suzy Biszantz as CEO and Virginie Troudet as CFO, while co-founder Jane Gottschalk resigned as President and director to become a senior advisor. The company also appointed three new directors to its board, including Toby Maitland Hudson and Ben Pruess, and transitioned Max Gottschalk to a non-executive director role. These changes are intended to support the company's next phase of growth and align executive responsibilities with strategic priorities.

3:44 PM ET 8-K
Product Launch Bioxytran, Inc BIXT

Bioxytran Product Launch

Bioxytran, Inc. announced the commercial launch of its first two nutraceutical products, A-SUQAR for metabolic support and V-LO for immune support. The launch marks the clinical-stage biotech's expansion into the consumer wellness market, utilizing its carbohydrate-chemistry expertise. Both products are available immediately through the company's online storefront.

“For years, our team has worked on complex therapeutics for critical care and infectious diseases. Today we are bringing that same science directly to people’s doorsteps. Our entry into nutraceuticals is driven by a simple principle: apply rigorous scientific standards to everyday health. We have held these products to the same diligence we apply to our drug programs, so consumers get a high-quality, science-backed supplement they can trust.”

David Platt, Ph.D., Chief Executive Officer of Bioxytran
3:44 PM ET 8-K
Financial Results Reading International Inc RDI

Reading International Financial Results

Reading International reported its best third-quarter operating income since 2016, driven by record-breaking box office performance from 'Spider Man: Brand New Day' and 'The Odyssey'. Total revenues grew 25% year-over-year to $65.3 million, while net income turned positive at $0.5 million compared to a loss in the prior year period.

Term
Q3 2026

“Following a strong second quarter, we once again delivered strong operational results in the third quarter 2026 with our third quarter Operating Income, EBITDA, Basic Earnings per Share and Net Income delivering better results than pre-pandemic third quarter periods, despite having sold 10 properties since Q3 2019 and having reduced our global cinema screen count by 5%.”

Ellen Cotter, President and Chief Executive Officer
3:42 PM ET 10-Q
Financial Results Quarta-Rad, Inc. QURT

Quarta-Rad Q3 2026 Results: Net Loss of $42.5K, Loss Narrows

Quarta-Rad, Inc. reported a net loss of $181,456 for the nine months ended September 30, 2026, as it continues to wind down its legacy radiation business to focus on its AI software subsidiary, Sellavir, Inc. Total sales decreased from $162,686 to $129,618 year-over-year, and the company reported a stockholders' deficit of $38,921.

Key figure
Net loss $42.5K
3:42 PM ET 10-Q
Financial Results Polomar Health Services, Inc. PMHS

Polomar Health Services Q3 2026 Results: Net Loss of $514K, Loss Narrows

Polomar Health Services, Inc. reported a significant revenue increase to $3.74 million for the nine months ended September 30, 2026, compared to just $16,174 in the prior year period. Despite this growth, the company incurred a net loss of $829,002 and maintains a stockholders' deficit of $2.84 million, though it achieved positive cash flow from operations of $193,996.

Key figure
Net loss $514K
3:42 PM ET 10-Q
Financial Results Goldenwell Biotech, Inc. GWLL

Goldenwell Biotech Q3 2026 Results: Net Loss of $31.5K, Loss Widens

Goldenwell Biotech Inc. reported a net loss of $86,022 for the nine months ended September 30, 2026, with zero revenue generated during the period. The company faces substantial doubt about its ability to continue as a going concern due to an accumulated deficit of $1,742,138 and limited cash reserves of $788.

Key figure
Net loss $31.5K
3:26 PM ET 10-Q
Financial Results Reading International Inc RDI

Reading International Q3 2026 Results: Turns Profitable, Net Income $467K

Reading International reported a net income of $0.5 million for the quarter ended September 30, 2026, a significant improvement from a $4.3 million loss in the prior year period, driven by a 25% increase in total revenue. However, for the nine months ended September 30, 2026, the company remains in a net loss position of $5.3 million with a total stockholders' deficit of $22.2 million.

Key figure
Net income $467K

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.